Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Versluis, J.M."'
Autor:
Versluis, J.M., Hoefsmit, E.P., H. Shehwana, Dimitriadis, P., Sanders, J., Broeks, A., Blank, C.U.
Publikováno v:
In Immuno-Oncology and Technology December 2022 16 Supplement 1
Autor:
Reijers, Dimitriadis, P., Traets, J.J., Saw, R., Versluis, J.M., Pennington, T., Kapiteijn, E., Van der Veldt, A.A.M., Suijkerbuijk, K., Hospers, G., Van Houdt, W., Broeks, A., Cornelissen, S., Spillane, A., Scolyer, R., van de Wiel, B., Menzies, A.M., van Akkooi, A.C.J., Long, G.V., Blank, C.U.
Publikováno v:
In Immuno-Oncology and Technology December 2022 16 Supplement 1
Autor:
Versluis, J.M.1 (AUTHOR), Menzies, A.M.2,3,4 (AUTHOR), Sikorska, K.5 (AUTHOR), Rozeman, E.A.1 (AUTHOR), Saw, R.P.M.2,3,6,7 (AUTHOR), van Houdt, W.J.8 (AUTHOR), Eriksson, H.9,10 (AUTHOR), Klop, W.M.C.11 (AUTHOR), Ch'ng, S.2,6,7 (AUTHOR), van Thienen, J.V.1 (AUTHOR), Mallo, H.1 (AUTHOR), Gonzalez, M.2 (AUTHOR), Torres Acosta, A.5 (AUTHOR), Grijpink-Ongering, L.G.5 (AUTHOR), van der Wal, A.5 (AUTHOR), Bruining, A.12 (AUTHOR), van de Wiel, B.A.13 (AUTHOR), Scolyer, R.A.2,3,14,15 (AUTHOR), Haanen, J.B.A.G.1,16 (AUTHOR), Schumacher, T.N.17,18 (AUTHOR)
Publikováno v:
Annals of Oncology. Apr2023, Vol. 34 Issue 4, p420-430. 11p.
Autor:
Rozeman, E.A., Versluis, J.M., Moritz, R., Wilgenhof, S., Thienen, J.V. van, Haanen, J.B.A.G., Heuvel, M.M. van de, Blank, C.U., Rossum, H.H. van
As a subset of advanced melanoma patients derive long-term benefit from anti-PD-1 therapy, early identification of non-responsiveness would enable an early switch to next line therapies. This study assessed if an early increase in S100B or lactate de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______202::74559060cacad62ee9a1c4a1d65313e4
https://hdl.handle.net/1887/3627563
https://hdl.handle.net/1887/3627563
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Versluis, J.M., Reijers, I.L.M., Rozeman, E.A., Menzies, A.M., Akkooi, A.C.J. van, Wouters, M.W., Ch'ng, S., Saw, R.P.M., Scolyer, R.A., Wiel, B.A. van de, Schilling, B., Long, G.V., Blank, C.U.
Publikováno v:
European Journal of Cancer, 148, 51-57. ELSEVIER SCI LTD
Background: Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoad-juvant ipilimumab plus nivolumab induces high pathologic response rates and an imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1fde8b660487a3300247bf460369d7bd
https://hdl.handle.net/1887/3276135
https://hdl.handle.net/1887/3276135
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S674-S674
Autor:
Lucas, M.W., Rozeman, E.A., Versluis, J.M., Menzies, A.M., Eriksson, H., van de Wiel, B., Scolyer, R., van Thienen, H.V., Mallo, H., Gonzalez, M., Landman, L., Torres Acosta, A., Grijpink-Ongering, L., Haanen, J.B.A.G., van Akkooi, A.C.J., Long, G.V., Blank, C.U.
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S660-S661
Neoadjuvant chemo(radio)therapy is part of the established standard of care in cancer treatment; neoadjuvant application of immunotherapy, however, is only performed within recent trials. Combination of programmed cell death protein 1 and cytotoxic T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______202::b52bbcc3e2b8ee526f6a30e2b363084c
https://hdl.handle.net/1887/3627295
https://hdl.handle.net/1887/3627295
Autor:
Rozeman, E.A., Hoefsmit, E.P., Reijers, I.L.M., Saw, R.P.M., Versluis, J.M., Krijgsman, O., Dimitriadis, P., Sikorska, K., Wiel, B.A. van de, Eriksson, H., Gonzalez, M., Acosta, A.T., Grijpink-Ongering, L.G., Shannon, K., Haanen, J.B.A.G., Stretch, J., Ch'ng, S., Nieweg, O.E., Mallo, H.A., Adriaansz, S., Kerkhoven, R.M., Cornelissen, S., Broeks, A., Klop, W.M.C., Zuur, C.L., Houdt, W.J. van, Peeper, D.S., Spillane, A.J., Akkooi, A.C.J. van, Scolyer, R.A., Schumacher, T.N.M., Menzies, A.M., Long, G.V., Blank, C.U.
Publikováno v:
Nature medicine. 27(2)
Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN () and phase 2 OpACIN-neo () studies(1,2). While the results are promising, data on the durabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::dbfbb947e633ca7e4bb86f138903fd79
https://pubmed.ncbi.nlm.nih.gov/33627793
https://pubmed.ncbi.nlm.nih.gov/33627793